Nektar Therapeutics may have a pipeline-in-a-drug with rezpegaldesleukin, has additional readouts ahead, and cash until 2027.
Despite falling short of its primary Phase II objective, Nektar plans to push its T cell stimulator rezpeg into Phase III ...
Here are the top 5 most-viewed alopecia content in 2025.
Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...
USA: A new retrospective cohort study has found that alopecia areata (AA) —an autoimmune condition primarily known for ...
Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before ...
US biotech Nektar Therapeutics shares increased by 10% in pre-market trading following promising Phase IIb trial results.
Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...
Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology ...
Nektar Therapeutics released data from a study of its rezpegaldesleukin drug, establishing proof-of-concept in patients with severe to very severe alopecia areata, a hair-loss condition.
A Las Vegas woman who was crowned Miss Nevada in July made history at the Miss USA pageant by becoming the first contestant ...
A treatment for alopecia areata could move forward despite a setback in a midstage clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results